Panbela Therapeutics, Inc.
General ticker "PBLA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.2M (TTM average)
Panbela Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -44.0%.
Estimated limits based on current volatility of 17.6%: low 0.01$, high 0.02$
Factors to consider:
- Total employees count: 8 (+14.3%) as of 2023
- Top business risk factors: Lack of diversification, Negative cash flow, High capital expenditure requirements, Regulatory and compliance, Product liability
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [4.53$, 29.26$]
- 2024-12-30 to 2025-12-30 estimated range: [1.11$, 8.84$]
Financial Metrics affecting the PBLA estimates:
- Negative: with PPE of -0.0 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -1111309.01 <= 0.33
- Negative: negative Net income
- Negative: Shareholder equity ratio, % of -39.91 <= 18.93
- Negative: negative Industry operating cash flow (median)
- Negative: negative Industry operating income (median)
- Negative: -0.15 < Industry inventory ratio change (median), % of 0
- Negative: -0.75 < Inventory ratio change, % of 0
Short-term PBLA quotes
Long-term PBLA plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $10.01MM | $34.09MM | $25.65MM |
| Operating Income | $-10.01MM | $-34.09MM | $-25.65MM |
| Non-Operating Income | $-0.61MM | $-0.96MM | $0.20MM |
| Interest Expense | $0.01MM | $0.29MM | $0.32MM |
| R&D Expense | $5.42MM | $28.05MM | $20.61MM |
| Income(Loss) | $-10.62MM | $-35.05MM | $-25.45MM |
| Taxes | $-0.49MM | $-0.12MM | $-0.19MM |
| Profit(Loss)* | $-10.13MM | $-34.93MM | $-25.26MM |
| Stockholders Equity | $10.21MM | $-8.05MM | $-4.71MM |
| Assets | $12.87MM | $4.98MM | $11.80MM |
| Operating Cash Flow | $-6.70MM | $-15.28MM | $-25.25MM |
| Capital expenditure | $0.00MM | $0.66MM | $0.00MM |
| Investing Cash Flow | $-0.54MM | $-0.66MM | $0.40MM |
| Financing Cash Flow | $10.10MM | $5.35MM | $26.14MM |
| Earnings Per Share** | $-20,773.70 | $-40,748.57 | $-232,429.55 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.